Immune, targeted therapy and related issues of relapsed/refractory multiple myeloma / 国际肿瘤学杂志
Journal of International Oncology
;
(12): 381-384, 2021.
Article
in Chinese
| WPRIM
| ID: wpr-907550
ABSTRACT
The new immune and targeted therapy medicines of multiple myeloma and recurrence of refractory multiple myeloma mainly include immunomodulatory drugs, proteasome inhibitors, monoclonal antibody, immune monitoring point inhibitors, histone deacetylase and chimeric antigen receptor. Although the emergence of new drugs and the application of autologous hematopoietic stem cell transplantation have significantly improved the prognosis of patients, more effective treatment methods and treatment strategies are still required to deal with the adverse reactions and the condition of recurrence during treatment.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Journal of International Oncology
Year:
2021
Type:
Article
Similar
MEDLINE
...
LILACS
LIS